A discrepancy between Tc-99m HMPAO SPECT and Tc-99m ECD SPECT in Creutzfeldt-Jacob disease

Ichiro Sunada1, Toru Ishida, Shinichi Sakamoto

  • 1Department of Neurosurgery, Saiseikai Ibaraki Hospital, Mitsukeyama, Ibaraki 567-0035, Japan.

Insights

Technetium-99m ethyl cysteinate dimer SPECT (ECD-SPECT) better correlated with Creutzfeldt-Jacob disease (CJD) pathology than technetium-99m hexamethyl propylene amine oxime SPECT (HMPAO-SPECT). ECD-SPECT revealed bifrontal hypoperfusion matching autopsy findings in CJD.

Area of Science:

  • Neurology
  • Radiology
  • Pathology

Background:

  • Creutzfeldt-Jacob disease (CJD) is a rapidly progressive neurodegenerative disorder.
  • Cerebral perfusion imaging using single photon emission computed tomography (SPECT) can aid in diagnosing CJD.
  • Technetium-99m hexamethyl propylene amine oxime (HMPAO) and technetium-99m ethyl cysteinate dimer (ECD) are common SPECT radiotracers.

Observation:

  • A discrepancy was noted in SPECT perfusion patterns between HMPAO-SPECT and ECD-SPECT in an 84-year-old CJD patient.
  • HMPAO-SPECT showed parieto-temporal hypoperfusion, particularly in the left temporal lobe.
  • ECD-SPECT revealed significant bifrontal hypoperfusion.

Findings:

  • Autopsy confirmed CJD pathology, with spongiform vacuolation most prominent in the bifrontal regions.
  • The observed bifrontal hypoperfusion on ECD-SPECT correlated better with the pathological findings than the parieto-temporal findings on HMPAO-SPECT.
  • This suggests ECD may be more sensitive in detecting the specific perfusion deficits associated with CJD.

Implications:

  • ECD-SPECT may offer a more accurate assessment of CJD-related perfusion deficits compared to HMPAO-SPECT.
  • Findings could influence diagnostic strategies and interpretation of SPECT imaging in CJD cases.
  • Further studies are warranted to validate the differential utility of ECD and HMPAO in CJD diagnosis.